Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Kit used for evaluating ovarian cancer primary chemotherapeutic sensitivity, and application thereof

An ovarian cancer and kit technology, which is applied to an ovarian cancer primary chemotherapy sensitivity evaluation kit and its application field, can solve the problems of delaying treatment opportunities and increasing patient suffering.

Inactive Publication Date: 2012-05-02
DALIAN MEDICAL UNIVERSITY
View PDF7 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Furthermore, as mentioned above, the drugs used clinically to treat ovarian cancer have not relieved the symptoms of a considerable number of patients, but this can only be discovered after a long clinical period, which often leads to delays in treatment opportunities and increases the number of patients. pain

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Kit used for evaluating ovarian cancer primary chemotherapeutic sensitivity, and application thereof
  • Kit used for evaluating ovarian cancer primary chemotherapeutic sensitivity, and application thereof
  • Kit used for evaluating ovarian cancer primary chemotherapeutic sensitivity, and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0076] I. Specimen Collection

[0077] 71 paraffin samples of serous ovarian cancer tissue preserved by the Department of Pathology, Dalian Obstetrics and Gynecology Hospital were collected from patients with serous ovarian cancer undergoing radical resection in the hospital. % formalin fixed, embedded in paraffin, and stored at room temperature.

[0078] II. Sample pretreatment, including the following steps:

[0079] a. Dewaxing: Ovarian cancer formalin-fixed paraffin-embedded tissue routine sections, paraffin tissue sections with a thickness of 4-5 μm were dewaxed 3 times in 100% xylene, 5 minutes each time; dewaxed 3 times in absolute ethanol , 2 minutes each time; 95% ethanol, 90% ethanol, 70% ethanol, 50% ethanol were dewaxed once, 2 minutes;

[0080] b. Antigen retrieval: carry out antigen retrieval with 0.01M citrate buffer, then wash with PBS 3 times, 5 minutes each time;

[0081] c. Eliminate endogenous peroxidase: place the tissue section in 3% hydrogen peroxide,...

Embodiment 2

[0104] Using the primary chemotherapy-sensitive cells (OV2008) and drug-resistant cells (C13) of ovarian cancer patients recognized by the NCI (National Cancer Institute) in the United States (Yamamoto K, et al.: Heat shock protein 27 wasup-regulated in cisplatin resistant human ovarian tumor cell line and associated with the cisplatin resistance. Cancer Lett. 2001, 168: 173-181; Xu G, et al: Nodal Induces Apoptosis and Inhibits Proliferation in Human Epithelial Ovarian Cancer Cells via Activin Receptor-Like Kinase 7. The Journal of Clinical Endocrinology & Metabolism 89 (2004. 11): 5523-5534), using immunofluorescence detection (immunofluorescence IF), immunohistochemical reaction (IHC) and improved Western Blotting method (Lee B et al. Perlecan domain V is neuroprotective and proangiogenic following ischemic stroke in rodents.J Clin Invest .2011Jul 11.pii:46358.doi:10.1172 / JCI46358), verified the different expression of ERCC2 in primary chemotherapy-sensitive cells (OV2008) a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Thicknessaaaaaaaaaa
Login to View More

Abstract

The invention discloses a kit used for evaluating ovarian cancer primary chemotherapeutic sensitivity, and an application thereof. The kit comprises a blocking reagent, an antigen-antibody reaction system, an avidin-oxide enzyme reaction system and a counterstaining drug. The invention is provided based on the relevance between the expression level of ERCC2 in serous ovarian cancer cells / tissues and sensitivity of cells, tissues or a tumor patient as a host to a primary chemotherapeutic drug. Through ERCC2 detection, purposes such as chemotherapeutic sensitivity / drug resistance evaluation, tumor patient discrimination, and primary chemotherapeutic drug tolerability evaluation can be achieved. The method provided by the invention is simple and accurate. The requirement on a sample is not high. Therefore, the kit and the method can be used in large-scale screening or trace researches. When the kit and the method is used in clinical diagnosis and medication guidance, ex vivo cancer tissues of a patient can be acquired for detection after operation, and the detection is characterized in no wound, no pain, and noninvasiveness. The detection can easily be accepted by patients. With the kit and the application, patient lives can be prolonged, chemotherapy pains of the patients can be alleviated, and life qualities of the patients after operations can be improved.

Description

technical field [0001] The invention relates to a kit for assessing chemotherapy sensitivity of ovarian cancer and its application in primary chemotherapy sensitivity / drug resistance assessment, tumor patient screening, and primary chemotherapy drug resistance assessment. Background technique [0002] Epithelial ovarian cancer (Epithelial Ovarian Cancer, EOC) is one of the common tumors of female reproductive organs, and it is the leading killer of female tumors. Among them, serous carcinoma is the most common, accounting for 80-85% of all ovarian cancers in Western countries, divided into advanced and early stages, of which the advanced stage accounts for the vast majority, and the early stage is very rare, accounting for <5% of all ovarian cancers. It is now considered that early and late serous carcinoma are two different types of ovarian cancer, and the difference in morphology actually reflects the difference in tumor biology, which in the final analysis is the diffe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/574
CPCG01N2333/4703G01N33/57449G01N33/6875G01N33/574
Inventor 崔世英丁艳芳赵瑾瑶杨亮毕丽华姜继勇
Owner DALIAN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com